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Numerous human diseases arise from alterations of genetic information, most notably
DNA mutations. Thought to be merely the intermediate between DNA and protein,
changes in RNA sequence were an afterthought until the discovery of RNA editing 30
years ago. RNA editing alters RNA sequence without altering the sequence or integrity
of genomic DNA. The most common RNA editing events are A-to-I changes mediated
by adenosine deaminase acting on RNA (ADAR), and C-to-U editing mediated by
apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 (APOBEC1). Both A-to-I
and C-to-U editing were first identified in the context of embryonic development and
physiological homeostasis. The role of RNA editing in human disease has only recently
started to be understood. In this review, the impact of RNA editing on the development
of cancer and metabolic disorders will be examined. Distinctive functions of each RNA
editase that regulate either A-to-I or C-to-U editing will be highlighted in addition to
pointing out important regulatory mechanisms governing these processes. The potential
of developing novel therapeutic approaches through intervention of RNA editing will be
explored. As the role of RNA editing in human disease is elucidated, the clinical utility of
RNA editing targeted therapies will be needed. This review aims to serve as a bridge of
information between past findings and future directions of RNA editing in the context of
cancer and metabolic disease.
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INTRODUCTION
Genetic complexity, or plasticity, is the foundation to develop complicated biological functions in
living organisms. To maximize the versatility of limited amounts of genetic material, a variety of
changes take place at the genomic level, including RNA metabolism and modification (1). RNA is
involved in some of the most evolutionarily conserved cellular processes, including transcription
and translation. The mechanisms of RNA regulation, including modification, processing and
degradation, have been extensively studied. Among these mechanisms, site-specific substitution
of RNA, or “RNA editing,” has garnered increasing attention in recent years, despite its discovery
more than 30 years ago.
The year of 1987 marked the first milestone for the journey of RNA-editing. A cytidine (C)
to uridine (U) conversion in the mRNA of human apolipoprotein B (apoB) was identified to
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be responsible for the production of a shorter version of apoB
(apoB48) by creating a new stop codon (2). This alteration
is mediated by an enzyme complex that contains the catalytic
deaminase, apolipoprotein B mRNA editing enzyme, catalytic
polypeptide 1 (APOBEC1) (3).
Meanwhile, a curious phenomenon of destabilization
of double-stranded RNA was observed during the early
embryogenesis of Xenopus laevis (4, 5). Hoping to use antisense
RNA inhibition to study genetic factors in the embryonic
development, investigators were surprised to learn that the
same technique that works well in early-stage oocytes was
not successful in later-stage oocytes and embryos due to
failed formation of RNA duplex. This observation prompted
speculations of a RNA-unwinding mechanism that either
controls RNA stability or helps RNAs shape their secondary
structures. It was further characterized by the loss of RNA’s
base-pairing properties and attributed to the conversion of
adenosines (A) to inosines (I), an activity later found to be
mediated by members of the adenosine deaminase acting on
RNA (ADARs) family (6–8).
In the last 30 years, the physiological functions of APOBEC
and ADAR protein family members have been gradually
revealed (9, 10). These RNA editing enzymes (referred to
as editases herein) can shuttle between the nucleus and
cytoplasm, and homodimerization is required for their catalytic
activity. APOBEC-mediated RNA editing has been implicated
in maintaining homeostasis in digestive organs, such as the
liver and small intestine, while ADAR-mediated RNA editing is
thought to play a crucial role in regulating the innate immune
response to infection. More recently, next generation sequencing
has expedited the identification of specific RNA-editing targets
and their associated functional consequences in human diseases.
The functional impact of RNA editing on cell biology is
demonstrated through (i) changing amino acid sequences of
proteins (recoding); (ii) altering splicing patterns of pre-mRNA;
(iii) causing changes in seed sequences of microRNAs (miRNAs)
or in sequences of miRNA targeting sites; and (iv) influencing the
stability of targeted RNAs (9, 10) (Figure 1).
This review aims to (1) provide a summary of recently
identified RNA-editing events that regulate both cancer
development and metabolic dysfunctions, (2) highlight the
existing gaps in our knowledge of RNA-editing mechanisms, and
(3) describe the potential implications for the development of
novel therapeutic approaches to regulate RNA editing.
RNA Editing in Cancer Development
Biogenesis of RNAs and RNA-regulated functions have been well-
established in playing important roles in tumorigenesis (11).
With the ability to change DNA-encoded genetic information
after transcription, deregulated RNA-editing could be an
important contributor in cancer development. Studies of RNA
editing in a variety of cancer types (mostly in the context of A-to-
I editing) have generated conflicting reports regarding the exact
role RNA-editing plays.
The consistent finding from these reports is that RNA
editing is a common phenomenon in cancer helping to drive
transcriptomic and proteomic diversity, and overall levels of
RNA editing mirror the expression levels of editases in cancers
compared to normal tissues (ex. overexpression= general hyper-
editing; reduced expression = general hypo-editing) (12–15).
In contrast, the relationship between the overall editing level
and tumorigenic potential of cancers appears to be unsettled.
Increased level of RNA editing has been found to correlate
with enhanced tumorigenesis in some cancers but reduced
tumorigenesis in others, sometimes with both correlations in the
same cancer type (12–14, 16–18).
These conflicting reports suggest that the relationship between
RNA editing and cancer development is complicated and
potentially influenced by other factors such as the origin,
stage and microenvironment associated with the studied cancer.
Instead of attempting to connect an individual cancer with the
global level of RNA editing, connecting specific RNA editing
events to cancer-related functions could prove to be more
informative.
ADAR1
Currently, three ADAR gene family members have been
identified and studied for their RNA-editing functions: ADAR1
(encoded byADAR), ADAR2 (encoded byADARB1) andADAR3
(encoded by ADARB2) (9).
The mRNAs of multiple proteins have been identified as direct
targets of ADAR1 and undergo nonsynonymous amino-acid
substitutions associated with cancer development (Figure 2).
In hepatocellular carcinoma (HCC), esophageal squamous cell
carcinoma (ESCC), colorectal cancer (CRC) and breast cancer
(BC), overexpression of ADAR1 leads to the creation of an
oncogenic version of antizyme inhibitor 1 (AZIN1; S367G).
Edited AZIN1 is stabilized and serves as an analog of ornithine
decarboxylase (ODC) to block antizyme-mediated degradation
of ODC and cyclin D1. Accumulations of ODC and cyclin D1
lead to increased cell proliferation and metastatic potential, as
well as tumor initiating capacity (17, 19–21). In cervical cancer
(CC), ADAR1 promotes tumorigenesis by editing multiple
sites within the YXXQ motif of bladder cancer-associated
protein (BLCAP), a tumor suppressor. Edited BLCAP loses its
ability to interact with and inactivate signal transducer and
activator of transcription 3 (STAT3), resulting in increased cell
proliferation (22).
ADAR1 can exert anti-tumorigenic activities through RNA
editing-mediated protein recoding, too. In BC, GABAA receptor
alpha 3 (GABRA3) activates the Akt pathway and promotes cell
migration, invasion and metastasis. ADAR1-mediated editing
of GABRA3 (I342M) reduces its cell surface expression and
suppresses Akt activation and metastatic potential of cancer
cells (23).
A recent study revealed a novel function of ADAR1 in cancer-
associated immune environment. In subsets of tumor samples,
including ovarian cancer (OC), melanoma and BC, increased
levels of ADAR1-edited peptides are presented by human
leukocyte antigen (HLA) molecules (24). Presentations of these
edited peptides, such as cyclin I (CCNI; R75G), elicit antigen-
specific killing of tumor cells through cytotoxic (CD8+) T cells. It
presents an intriguing possibility to explore immunotherapeutic
approaches utilizing information of RNA editing. Alternatively, it
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FIGURE 1 | RNA editing leads to functional consequences through multiple mechanisms. RNA editases (ADAR1, ADAR2, ADAR3, and APOBECs in this review)
regulate their targets through multiple mechanisms, including altering mRNA sequences in exons to change amino acid sequences (protein recoding; red arrows),
changing splicing patterns of pre-mRNA to create novel products (alternative splicing; orange arrows), influencing miRNA specificity by altering seed sequences of
miRNAs or sequences of miRNA targeting sites (miRNA specificity; green arrows), and directly impacting the stability of edited RNAs (RNA stability; magenta arrows).
X represents a RNA base targeted by RNA editases (Adenosine for ADARs; Cytidine or Guanosine for APOBECs), and Y represents the resultant RNA base after the
editing (Inosine for ADARs; Uridine or Adenosine for APOBECs). The hairpin structure in the mRNA represents Alu repeat elements that are frequently targeted by RNA
editases. UTR, untranslated region. The figure was created with BioRender.
also poses a potential mechanism that cancers can hijack in order
to avoid effective immune surveillance.
The boundary between pro-tumorigenic and anti-
tumorigenic functions of ADAR1 can be blurry even with
the same amino-acid-sequence-altering event. The glioma-
associated oncogene 1 (GLI1) activates the Hedgehog (HH)
signaling pathway to promote cell proliferation (25). In multiple
myeloma (MM), amplified ADAR1 edits GLI1 (R701G) and
stabilizes GLI1 expression by preventing the binding of its
negative regulator, suppressor of fused (SUFU). Edited GLI1
displays higher transcriptional activity to drive HH signaling
and promote malignant regeneration and drug resistance of
MM (26). Interestingly, this exact same editing event has
the opposite effect in medulloblastoma (MB) and basal cell
carcinoma (BCC) to inhibit tumorigenesis. ADAR1-edited GLI1
(R701G), despite its resistance to SUFU binding, also becomes
much less accessible to one of its activators, Dual specificity
tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). The
net result is reduced oncogenic potential of edited GLI1 in MB
and BCC (27).
In metastatic melanoma, ADAR1 confers tumor-suppressive
activities by editing miRNA sequences to alter their target
specificity. ADAR1-mediated editing of miR455-5p results
in lack of inhibition of the tumor suppressor cytoplasmic
polyadenylation element-binding protein 1 (CPEB1), while
edited miR378a-3p targets the oncogene, α-Parvin, for
downregulation (28, 29). During the course of melanoma
progression, transcriptional repressors of ADAR1, such as
cyclic AMP-responsive element binding protein (CREB),
are upregulated to reduce ADAR1 expression to promote
malignancy.
Not surprisingly, ADAR1 is also capable of hijacking the
miRNA biogenesis process to promote tumorigenesis. In blast
crisis chronic myeloid leukemia (BC CML), JAK2 activation
and BCR-ABL1 amplification was shown to increase ADAR1
expression promoting leukemia stem cell (LSC) self-renewal (30).
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FIGURE 2 | ADAR1-mediated RNA editing in cancer development. The color of the first arrow in each pathway indicates the mechanism (refer to Figure 1) by which
ADAR1 regulates its direct targets, depicted in pink icons or shapes. Dashed lines indicate suggested/unproven functions/relationships. Additional activators and
inhibitors of specific pathway steps are depicted in red and yellow rounded rectangles, respectively. Specific diseases and phenotypes/functions affected by
ADAR1-mediated RNA editing are only labeled in the first appearance (ex. proliferation…etc). HCC, hepatocellular carcinoma; ESCC, esophageal squamous cell
(Continued)
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FIGURE 2 | carcinoma; CRC, colorectal cancer; BC, breast cancer; CC, cervical cancer; OC, ovarian cancer; MM, multiple myeloma; MB, medulloblastoma; BCC,
basal cell carcinoma; CML, chronic myeloid leukemia; PC, prostate cancer; LUAD, lung adenocarcinoma; KC, kidney cancer; BLC, bladder cancer. The figure was
created with BioRender.
A follow-up study revealed that ADAR1 accomplishes this feat
by reducing the expression of the tumor-suppressive miRNA let-
7 (31). Mechanistically, overexpression of ADAR1 promotes the
induction of the pluripotency gene LIN28 and the editing of the
primary miRNA pri-let-7 at multiple sites, both events reduce the
production of let-7 family members (32, 33).
In addition to altering miRNAs directly, ADAR1 also edits
miRNA targets to affect their susceptibility to miRNA-mediated
repression. ADAR1 was shown to edit over two dozen sites on
the three prime untranslated region (3’UTR) of dihydrofolate
reductase (DHFR). In BC, edited DHFR becomes resistant to the
targeting of miR25-3p and miR125a-3p. As a result, the protein
levels of edited DHFR increase to promote cell growth and
resistance to chemotherapeutic agents like methotrexate (34).
ADARs have been shown to regulate RNA stability through
a variety of mechanisms, including alterations of subcellular
localization or changing the secondary structure of edited RNAs
(35–37). Although the detailed molecular processes remain
elusive, several recent studies highlighted ADAR1’s role in this
capacity to impact cancer development. In prostate cancer (PC),
ADAR1-mediated editing of prostate cancer antigen 3 (PCA3),
an intronic long noncoding RNA, increases its stability and
expression. PCA3 acts as a dominant-negative oncogene and
forms a double-stranded RNA with precursor mRNA (pre-
mRNA) of prune homolog 2 (PRUNE2), a tumor suppressor
gene (38). The formation of the PCA3-PRUNE2 complex
promotes tumorigenesis in cell and mouse models through the
downregulation of PRUNE2, whose expression also inversely
correlates with PCA3 in human PC samples.
ADAR1-mediated RNA editing also occurs within the introns
of protein-coding RNAs. One such example involves an
important facilitator of tumor metastasis, focal adhesion kinase
(FAK). In lung adenocarcinoma (LUAD), the most common
form of non-small cell lung cancer (NSCLC), ADAR1-mediated
editing of intron 26 of FAK results in increased stabilization of
FAK mRNA and protein. Induction of FAK contributes to cell
invasiveness and is associated with tumor recurrence in LUAD
patients (39).
A recent study linking ADAR1 to intron-editing showed
that ADAR1 edits the intron of heterogeneous nuclear
ribonucleoprotein L-like (HNRPLL) to create an additional
exon (E12A) for HNRPLL (40). E12A-containing HNRPLL acts
as an enhancer of oncogenic splicing factor serine/arginine
rich splicing factor 1 (SRSF1), resulting in a positive feed-back
loop to increase the abundance of E12A-containing HNRPLL
transcript. E12A-containing HNRPLL regulates expressions
of cyclin D1 and transforming growth factor beta receptor 1
(TGFBR1) to promote cell proliferation in kidney and bladder
cancers. Interestingly, this editing event is also mediated by
ADAR2, pointing to potential interactions between ADAR1- and
ADAR2-mediated RNA editing.
ADAR2
First cloned in 1996, ADAR2 is the second identified A-to-
I RNA editase that is also capable of editing itself (41, 42).
ADAR2 was first identified as the main RNA editase of glutamate
receptor subunit B (GluR-B) (Figure 3). Underediting of GluR-B
(Q607R) results in early-onset epilepsy in a mouse model (43).
Mice with mutant ADAR2 are also seizure-prone and experience
early postnatal death, establishing the functional significance of
ADAR2-mediated editing of GluR-B (44, 45). The translational
impact of this connection was found in malignant human brain
tumors in both adults and children, where ADAR2-mediated
editing of GluR-B is reduced compared to control samples.
Although brain tumors are not present in ADAR2-mutant mice,
likely due to early postnatal death, these observations potentially
explain the aggressive nature of these cancers and neurologic
symptoms suffered by human patients (16, 46).
These early studies inspired mechanistic investigations to
directly link ADAR2 with malignant brain tumors such as
high-grade astrocytoma or glioblastoma multiforme (GBM). The
same team that made the initial connection between ADAR2-
mediated RNA editing and brain tumors identified several
pathways downstream of ADAR2 regulating GBM pathogenesis.
By editing multiple sites within intron 7 of the CDC14B
phosphatase pre-mRNA, ADAR2 promotes upregulation of
CDC14B, subsequently causing the degradation of E3-ligase S-
phase kinase-associated protein 2 (SKP2) (47, 48). In GBM,
downregulation of ADAR2-mediated RNA editing of CDC14B
results in overexpression of SKP2. Increased level of SKP2
then leads to ubiquitin-mediated degradation of cell cycle
inhibitors, p27Kip1 and CDKN1A/p21Cip1/Waf1, to promote cell
cycle progression and tumorigenesis.
Interestingly, ADAR2-mediated downregulation of p27 is
also connected to ADAR2’s ability to edit selected miRNAs
in the brain. ADAR2-mediated editing reduces expression
of oncogenic miRNAs, such as miR21 and miR221/222. In
GBM, failed editing/reduction of miR21 and miR221/222
lead to downregulation of their respective targets, tumor
suppressors programmed cell death protein 4 (PDCD4) and
p27Kip1 (49).
ADAR2 was found to edit numerous miRNAs, regulating
tumorigenesis by balancing the functions of oncogenic and
tumor-suppressive miRNAs (49, 50). This “balancing act”
of ADAR2 can also be achieved by switching miRNAs
between their oncogenic and tumor-suppressive activities
via altering target specificities. The first such example was
demonstrated by ADAR2’s ability to edit miR376a to inhibit
GBM progression (51). ADAR2-edited miR376a targets and
downregulates autocrine motility factor receptor (AMFR) to
inhibit tumor migration and invasion. Unedited miR376a,
however, switches its affinity from AMFR to Ras-related
protein RAP2A, a tumor suppressor protein acting on actin
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FIGURE 3 | ADAR2-mediated RNA editing in cancer development. The color of the first arrow in each pathway indicates the mechanism (refer to Figure 1) by which
ADAR2 regulates its direct targets, depicted in pink icons or shapes. Dashed lines indicate suggested/unproven functions/relationships. Specific diseases and
phenotypes/functions affected by ADAR2-mediated RNA editing are only labeled in the first appearance (ex. brain cancer). HCC, hepatocellular carcinoma; ESCC,
esophageal squamous cell carcinoma; CRC, colorectal cancer. The figure was created with BioRender.
remodeling. In GBM, deactivated ADAR2 flips the switch
through miR376a to tilt the balance toward malignant tumor
progression.
A recent study revealed another ADAR2-controlled switch
through miRNA editing in GBM. In normal brain tissues,
ADAR2 edits nearly 100% of miR589-3p to target and
reduce expression of disintegrin and metalloproteinase domain-
containing protein 12 (ADAM12), a metalloprotease that
promotes cancer metastasis. In high-grade GBM, editing of
miR589-3p decreases dramatically and unedited miR589-3p
targets protocadherin 9 (PCDH9), a tumor suppressor protein,
instead (52). These studies likely represent only a small
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percentage of such “switches” regulating pathogenesis of GBM
and other cancers.
In addition to GBM, ADAR2 also displays tumor-suppressive
functions in other types of cancer. ADAR2 is downregulated
in ∼50% of HCC and overexpression of ADAR2 in ADARs-
deficient HCC cells reduces their oncogenic potential (53).
ADAR2’s HCC-suppressing function is thought to be mediated
through editing coatomer protein complex subunit α (COPA)
mRNA (I164V), whose editing level inversely correlates with
HCC pathogenesis. The lack of ADAR2-mediated editing of
COPA was also observed in aggressive subtypes of CRC with
an epithelial-to-mesenchymal (EMT) phenotype leading to liver
metastasis (54).
Curiously, this seemingly straightforward assertion of
“ADAR2 edits COPA to suppress tumorigenesis” is complicated
by recent studies showing that (i) ADAR2 is overexpressed in a
small subset of HCC (55); and (ii) edited COPA has been shown
to promote a malignant phenotype of BC cells in vitro (15). This
suggests that RNA-editing mechanism is subject to complex
regulations to contribute to cancer-specific phenotypes.
ADAR2 can also serve as a dual-role regulator in esophageal
cancers. In ESCC where ADAR2 is downregulated, reduced
editing and expression of insulin-like growth factor-binding
protein 7 (IGFBP7; K95R) lead to activation of Akt and inhibition
of programmed cell death (56). In contrast, ADAR2 is a potential
predisposing factor in familiar ESCC. Elevated levels of ADAR2
lead to editing and reduction of solute carrier family 22member 3
(SLC22A3; N72D), which in turn promotes metastasis in familial
ESCC by inhibiting the interaction between SLC22A3 and its
inhibitory target α-actinin-4 (ACTN4), an actin-binding protein
facilitating filopodia formation (57).
A recent study described an interesting “tug-of-war”
relationship between ADAR2 and ADAR1 in gastric cancer
(GC). Unedited podocalyxin-like protein (PODXL) promotes
GC tumorigenesis by regulating cell adhesion mechanisms.
PODXL can be targeted by both ADAR1 and ADAR2 to
cause synonymous (ACA>ACG; T238T) and nonsynonymous
(CAC>CGC; H241R) amino acid substitutions, respectively. In
normal tissues, high ratio of ADAR2/ADAR1-mediated editing
keeps PODXL in its edited form (H241R) preventing oncogenic
onset. In GC, amplification of ADAR1 and reduction of ADAR2
cause imbalanced editing of PODXL to accumulate unedited
PODXL to drive tumorigenesis (58).
ADAR3
Few studies have focused on investigating ADAR3’s functional
importance in RNA editing. ADAR3 shares significant sequence
and structural similarities with ADAR1 and ADAR2, including
nuclear localization, deaminase, and RNA-binding domains (59).
Despite these similarities, ADAR3 has not been shown to display
deaminase activity to influence physiological functions such as
cancer development. A recent study demonstrated that ADAR3
may instead act as a dominant-negative form of other ADARs.
Overexpressed in GBM compared to normal brain tissues,
ADAR3 competes with ADAR2 for binding and editing of GluR-
B through its RNA-binding domain (60). Given the observation
that ADAR3 is expressed primarily in the brain, it is reasonable
to speculate that ADAR3 regulates tumorigenesis of brain cancers
by modulating ADAR2/ADAR1-mediated RNA editing (61).
APOBECs
In the human genome, there are eleven genes that belong
to the APOBEC protein family. Functionally, APOBECs are
cytidine deaminases and evolutionally conserved in vertebrates.
The majority of research activities regarding APOBECs have
focused on their ability to restrict viral infections by creating
mutational imbalances in the viral genome (62). Recent
developments, however, identified several APOBEC proteins,
particularly APOBEC3 subfamily members (A3A, A3B, and
A3H), being capable of catalyzing hypermutations in cancers to
drive tumorigenesis and therapy resistance (63, 64). Interestingly,
these connections have mostly been made with APOBECs’ ability
to modify single-stranded DNA instead of mRNA, despite what
their names indicate (65).
So far, APOBEC1 is the most well-established APOBEC
member that displays RNA editing activities (Figure 4). The first
direct connection between APOBEC1-mediated RNA editing
and tumorigenesis was made in 1995, when transgenic rabbits
and mice expressing rabbit APOBEC1 in livers developed HCC
(66). This outcome was found to be associated with hyperediting
and reduced expression of a translational repressor NAT1 (novel
APOBEC1 target no.1; also known as eukaryotic translation
initiation factor 4 gamma 2, or EIF4G2), which regulates
the expression of cell cycle inhibitor CDKN1A/p21Cip1/Waf1
(67, 68). APOBEC1 was also shown to bind the 3′UTR
of c-myc mRNA to increase its stability (69). These results
suggest that APOBEC1 might affect expression levels of
tumor-associated genes via its RNA-binding and –editing
capabilities.
Similar to its ability to edit apoB mRNA to create a
truncated form apoB48 (Q2153Stop), APOBEC1 was found
to edit the mRNA of neurofibromin 1 (NF1) to generate a
truncated NF1 (R1306Stop) in a subset of peripheral nerve–
sheath tumor (PNSTs) samples (70). It results in inhibition
of the tumor-suppressor function of NF1, and could be
responsible for development of neuronal tumors associated with
Neurofibromatosis (NF) Type 1 (71, 72). Interestingly, increased
expression of APOBEC1 and editing of NF1 were also found in
CRC, suggesting that other tumor types could also be affected by
this pathway (73).
Unconventional G-to-A RNA edits were identified
in the mRNA of Wilms Tumor 1 (WT1) (74). These
modifications increase in non-progenitor umbilical cord blood
mononuclear cell samples (CBMCs) compared to acute myeloid
leukemia (AML), implicating their roles in tumorigenesis.
RNA interference screening identified APOBEC3A as the
responsible RNA editase, opening up the possibility to
investigate the relationships between all APOBEC members
and cancer-associated RNA editing events. Interestingly, a
functionally-important RNA conversion between C and U was
also observed in WT1 in rat kidney during development (75). It
is unclear which RNA editase is responsible for this conversion,
but the fact that APOBEC1 is the only known C-to-U editase
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FIGURE 4 | APOBECs-mediated RNA editing in cancer development. The color of the first arrow in each pathway indicates the mechanism (refer to Figure 1) by
which APOBECs regulates its direct targets, depicted in pink shapes. Dashed lines indicate suggested/unproven functions/relationships. CRC, colorectal cancer;
PNST, peripheral nerve-sheath tumor; AML, acute myeloid leukemia. The figure was created with BioRender.
suggests that WT1 could be subject to RNA editing mediated by
multiple APOBECs.
RNA Editing in Metabolic Functions and
Disorders
The fact that RNA editases (ADARs and APOBEC1) are
expressed in major metabolic organs, such as the liver and
pancreas, offers an initial clue that RNA-editing might play
an important role in metabolic regulation (3, 76, 77). Deep-
sequencing data collected longitudinally from one individual
predisposed to and diagnosed with type 2 diabetes suggested
that RNA-editing could have predictive and diagnostic values
across healthy and diseased states (78). Moreover, RNA editing
events in diabetes-associated genes were identified in human
pancreatic islets from 89 deceased donors in an effort to
uncover genetic mechanisms affecting glucose metabolism
(79).
There is evidence to suggest that the RNA editing machinery
is one of the evolutionarily-adaptive mechanisms developed
while living organisms were becoming more complex. A-to-I
RNA editing occurs mainly in primate-specific Alu repetitive
elements that form secondary structures of dsRNA (80, 81).
APOBEC1-mediated editing of apoB, thus the production of
apoB48, only occurs in mammals (82). Evolutionarily-aligned
genetic alterations are thought to have important metabolic
consequences (83). Such speculation is prevalent when debating
the origins of human metabolic diseases, hence the proposal
of the thrifty gene hypothesis (84). Due to the lack of proper
experimental models, few genetic events have been functionally
proven to influence metabolic disorders in human. One recent
example is the codon 72 polymorphism (Pro72Arg or P72R) in
the tumor suppressor protein TP53 (85). The ancestral variant
of this polymorphism (P72) is only present in primates, while
the diversion from P72 to R72 only arose during the modern
human evolution (86). Using cell and transgenic mouse models,
the P72 variant was found to be a stronger responder tometabolic
stresses to cause cell death, and the R72 variant is a predisposing
factor for diet-induced obesity and diabetes (87, 88). Through
its ability to regulate numerous target genes, RNA editing has
potential to cause broader effects on human metabolic health
than a single genetic alteration such as a mutation or a genetic
polymorphism.
ADAR1
It has been suggested that ADAR1 expression in the liver
is important for early embryonic development. The absence
of ADAR1 in the mouse liver results in impaired embryonic
erythropoiesis, liver disintegration, and early death of the fetus
(76, 89). Mechanistically, ADAR1 protects liver homeostasis by
inhibiting inflammation (Figure 5). Silencing ADAR1 in liver
cells induces levels of pro-inflammatory cytokines and type I
interferons, partially through the NFκB pathway, to cause liver
damage through inflammation, lipid accumulation, hepatitis and
fibrosis (90, 91). ADAR1’s ability to maintain liver homeostasis
partially relies on its RNA-editing function, but no specific
editing target has yet been identified as the responsible effector
(90).
ADAR1-mediated RNA editing has recently been shown to
contribute to cardiovascular disease (CVD). One mechanism
for ADAR1 to promote CVD is through the phenotypic
modulation of smooth muscle cells (SMC), a pivotal step during
the development of CVD. The signature characteristic for the
phenotypic modulation of SMC is the downregulation of SMC-
specific genes, such as smooth muscle myosin heavy chain (SM-
MHC) and smooth muscle α-actin (ACTA2), often mediated
by platelet-derived growth factor (PDGF)-BB. In response to
PDGF-BB, ADAR1 edits pre-mRNA of these SMC genes to
cause abnormal splicing and subsequent downregulation of their
mRNAs (92).
ADAR1’s role to attenuate an aberrant innate immune
response has been well established (93, 94). Its ability to
inhibit unwanted inflammation also manifests in the form of
Aicardi-Goutières syndrome (AGS), an autoimmune disease
caused by ADAR1 mutations (95). Interestingly, ADAR1 acts
as a promoting factor in the context of inflammation-driven
CVD. Under hypoxia or pro-inflammatory conditions, ADAR1
expression is induced in endothelial cells to edit the 3
′
UTR
of cathepsin S (CTSS) mRNA. This editing event promotes
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FIGURE 5 | ADAR1-mediated RNA editing in metabolic disorders. The color of the first arrow in each pathway indicates the mechanism (refer to Figure 1) by which
ADAR1 regulates its direct targets, depicted in pink shapes. Additional activators of specific pathway steps are depicted in red rounded rectangles. Specific diseases
and phenotypes/functions affected by ADAR1-mediated RNA editing are only labeled in the first appearance (ex. CVD). CVD, cardiovascular disease; SMC, smooth
muscle cell. The figure was created with BioRender.
the recruitment of the RNA binding protein human antigen
R (HuR) to stabilize the mRNA of CTSS, a cysteine protease
known to be associated with atherosclerosis (96). Independent
of its involvement in the regulation of the immune system,
ADAR1 also plays critical roles regulating the development
and homeostasis of multiple organs, including the spleen, small
intestine, and kidney (97). These observations suggest that
ADAR1 could impactmetabolic functions in a systematicmanner
affecting multiple organs, possibly through its RNA-editing
capability.
The links between circadian rhythms, sleep, and metabolism
have been strengthened in recent years and presented as viable
targets of therapeutic intervention for metabolic diseases (98, 99).
A recent study, using Drosophila melanogaster as the model,
demonstrated that deficiencies in ADAR1 results in synaptic
dysfunction in glutamatergic neurons and sustained release of
neurotransmitter to promote sleep (100). It underlines the variety
of mechanisms ADAR1 could exploit to control an individual’s
susceptibility to metabolic disorders.
ADAR2
The first identified target of ADAR2-mediated RNA editing is
GluR-B, a subunit of the glutamate receptor (41). Around the
same time of this discovery, glutamate receptors were found to
regulate functions of pancreatic β-cells (101, 102). Despite this
hint, a decade would pass before ADAR2 was directly connected
to the metabolic functions of the pancreas (Figure 6). Using
levels of ADAR2 expression and GluR-B editing as indicators
in a mouse model, ADAR2 was found to be deactivated in
pancreatic β-cells during fasting and activated in response to
a high-fat diet (77). This regulation is mediated through the
JNK-c-Jun pathway, as JNK-phosphorylated c-Jun acts as the
transcription factor to induce ADAR2 expression in response to
nutrient stimulation (103). Activated ADAR2 in turn promotes
the secretion of insulin from the pancreas by influencing the
expression of key factors involved in exocytosis (104). It remains
to be seen if ADAR2-mediated editing of GluR-B is solely
responsible for ADAR2’s function in the pancreas, or if it involves
other ADAR2 targets.
Certain metabolic diseases, such as diabetes or obesity,
can manifest in the condition of hyperuricemia (abnormally
high uric acid level). Interestingly, increased levels of uric
acid were detected in the cortex of ADAR2-knockout mice
(105). Hyperuricemia mediated by the loss of ADAR2 in
the cortex correlates with the induction of phosphoribosyl
pyrophosphate synthetase 1 (PRPS1), an essential enzyme
involved in the synthesis of uric acid. Expression of PRPS1
is downregulated by miR376, whose seed sequence is
edited by ADAR2 to increase its hybridization with PRPS1
mRNA.
Due to ADAR2’s role in facilitating insulin secretion upon
nutrient stimulation and reducing uric acid levels, one would
assume that ADAR2 might be an active gate-keeper to prevent
metabolic diseases. ADAR2-transgenic mice, however, develop
hyperglycemia and severe obesity (106). ADAR2-induced obesity
in transgenic mice is the result of altered behavior patterns
presented in the form of addictive overeating (hyperphagia)
(106, 107). Whether ADAR2-mediated RNA editing is necessary
for this phenotype is unclear, as transgenic mice expressing
mutant ADAR2 (E396A), defective for RNA-editing ability,
developed similar levels of obesity compared to wild-type
ADAR2 (106). On the contrary, strong evidence does exist
to support the connection between ADAR2-mediated RNA
editing and hyperphagia. For example, expression and editing
levels of the ADAR2 target, serotonin 2C receptor (5-HT2cR),
correlate with ADAR2 expression in the brains of ADAR2-
transgenic mice and other mouse models of obesity (107,
108). In another study, transgenic mice solely expressing
the fully-edited isoform of 5-HT2cR developed phenotypic
characteristics of Prader-Willi syndrome (PWS), including
hyperphagia (109). PWS is a genetic imprinting disorder that
manifests in hyperphagia, early-onset obesity and diabetes. One
of the imprinting genes lost from the paternal copies in PWS
is the small nucleolar RNA (snoRNA) HBII-52 (MBII-52 in
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FIGURE 6 | ADAR2-mediated RNA editing in metabolic disorders. The color of the first arrow in each pathway indicates the mechanism (refer to Figure 1) by which
ADAR2 regulates its direct targets, depicted in pink icons or shapes. Dashed lines indicate suggested/unproven functions/relationships. Additional activators and
inhibitors of specific pathway steps are depicted in red and yellow rounded rectangles, respectively. CVD, cardiovascular disease. The figure was created with
BioRender.
mouse). MBII-52 was found to specifically inhibit ADAR2-
mediated RNA editing of 5-HT2cR, and loss of MBII-52
results in elevated 5-HT2cR RNA editing and PWS phenotypes
(110, 111).
In CVD patients, RNA editing of Filamin A (FLNA), an
actin crosslinking protein whose inactivation is linked to vascular
abnormalities, is significantly reduced. ADAR2 was identified
as the editase of FLNA, and ADAR2-edited FLNA (Q2341R)
prevents cardiac remodeling and hypertension (112). This is the
first known example linking ADAR2-mediated RNA editing to
development of CVD through regulation of vascular function
and blood pressure.
Like ADAR1, ADAR2 was also recently found to play a role
in regulating circadian rhythm. CLOCK (Circadian Locomotor
Output Cycles Kaput) – ARNTL (Aryl hydrocarbon Receptor
Nuclear Translocator-Like protein (1) protein complex, a critical
transcription factor during circadian cycles, was found to regulate
the expression of ADAR2 and ADAR2-mediated RNA editing
corresponding with the circadian rhythm in the liver (113).
ADAR2 contributes to circadian clock maintenance through a
couple mechanisms. First, ADAR2 regulates the recoding and
stability of a subset of “rhythmic genes,” whose expressions align
with the circadian cycle. Secondly, ADAR2 alters expression
levels of major “clock proteins” (whose expression is essential
for the circadian rhythmicity), such as Cryptochrome 2 (CRY2),
by regulating biogenesis of their targeting miRNAs (in the case
of CRY2, let-7) (114). ADAR2-knockout mice display disrupted
rhythms of fatty acid metabolism and gain excessive weight with
a high-fat diet, highlighting the significance of ADAR2 at the
intersection between circadian rhythm and metabolic regulation.
ADAR3
Other than its preferred presence in the brain and inability to
catalyze RNA editing on any proven target, little is known about
ADAR3’s functional connections to human diseases, including
metabolic disorders. The aforementioned study in glioblastoma
suggests a similar role for ADAR3 in metabolic diseases, as an
inhibitor of RNA editing mediated by other active editases (60).
Despite the lack of mechanistic data, the large amount of
genetic information available from the general population has
shed some light on potential connections between ADAR3
and metabolism. Multiple single nucleotide polymorphisms
(SNPs) in ADARB2 (encodes ADAR3) were found to be
associated with human longevity, using genetic information
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collected from centenarians in the US (115). Moreover, this
association was later linked to a variety of metabolic parameters,
including abdominal circumference, body mass index and serum
triglyceride level (116). While the correlation between ADAR3
and aging was preliminarily demonstrated in mutant strains of
Caenorhabditis elegans, more sophisticated models are needed
to establish ADAR3’s functional role in aging and metabolic
regulation (115).
APOBECs
The first identified, and most studied, RNA editing target
of APOBEC1 is apolipoprotein B (apoB; Q2153Stop) (2).
Unedited and edited apoB encodes for a full-length form
apoB100 and a truncated form apoB48, respectively. ApoB100
is synthesized in the liver and is a part of the assembly of
low density lipoprotein (LDL) and very low density lipoprotein
(VLDL), while apoB48 is mostly produced in the intestine
and is required for chylomicron formation and fat absorption
(117).
An elevated level of apoB100-containing LDL in the plasma is
one of the major characteristics in patients with atherosclerosis,
a disease state mimicked by mouse models that either lose
APOBEC1’s RNA editing activity or express apoB100 exclusively
(118–120) (Figure 7). A recent genome-wide association study
(GWAS) identified novel SNPs at APOBEC1 that are associated
with cholesterol composition, signifying APOBEC1’s role in
cholesterol-linked human diseases, such as atherosclerosis (121).
A transgenic rabbit model with reduced expression of
APOBEC1 presented a lean phenotype compared to wild type
when challenged with a high-fat diet (122). This phenotype
is consistent with (i) apoB48’s role in promoting chylomicron
formation and lipid absorption, and (ii) observations in earlier
studies that apoB48/apoB100 ratio and APOBEC1 expression
were higher in obese and diabetic rats (123, 124).
However, the relationship between apoB and metabolic
diseases is more complicated than just apoB48 (edited)
leading to diabetes/obesity and apoB100 (unedited) leading
to atherosclerosis. In an apoE-deficient mouse model, apoB48
promotes higher levels of cholesterol accumulation and
atherosclerotic lesion formation. This phenotype is the
manifestation of apoB48 being cleared exclusively through
apoE, while apoB100 can be cleared through the LDL receptor
alone (119, 125). On the other hand, links between apoB100
and obesity and diabetes have also been established. In rodent
models fed high-fat diets, accumulation of apoB100 in the
liver induces endoplasmic reticulum (ER) stress and insulin
resistance (126, 127). This phenotype is caused by JNK-
mediated phosphorylation of insulin receptor substrate (IRS-1),
a connection known to link ER stress, obesity and diabetes (128).
These studies highlight the significant connections between
apoB regulation, thus APOBEC1-mediated RNA editing, and
metabolic disorders. Despite efforts made to identify other RNA
editing targets of APOBEC1, no other target has yet been
shown to play a role connecting APOBEC1-mediated RNA
editing with metabolic disease (129). Data from one patient
with a predisposition to type 2 diabetes showed that C-to-U
editing is the second most frequent RNA editing event (next
to A-to-I), indicating that RNA editing mediated by APOBEC1
or other C-to-U editases is an important factor in metabolic
homeostasis (78).
Gap in Knowledge and Future Directions
The Complexity Between RNA Editases
An established link of “Enzyme-Target-Function” provides
the clearest blueprint to plan effective interventions of the
RNA editing machinery. Numerous examples mentioned in
this review fit this description providing multiple intervention
points, including modulation of the levels and activity of
editases, as well as correction of the edited target(s). There
are, however, plenty of ambiguities in the world of RNA
editing.
In the context of A-to-I editing, many disease-relevant editing
targets lack clear identification of the responsible editase(s). Such
examples include hyperediting-mediated alternative splicing of
protein tyrosine phosphatase PTPN6 in AML, and hyperediting-
activated ras homolog family member Q (RHOQ) in CRC (130,
131). In cases where involvement of editases were confirmed,
the relationships among editases could be complicated. For
example, ADAR1 and ADAR2, the two major A-to-I editases,
can display either collaborative or antagonistic functions
with each other. One example is the aforementioned editing
of PODXL in GC. The disease outcome is not controlled
by the function of one editase, but rather by the ratio
between ADAR1- and ADAR2-mediated PODXL editing (58).
More complications could come from ADAR3, whose role
in RNA editing is just starting to be appreciated (60,
115). The possibility remains that further identifications and
characterizations of proteins closely related to ADARs, such
as ADAD1 (Adenosine Deaminase Domain Containing 1) and
ADAD2, can further increase the complexity of A-to-I RNA
editing (9).
The functional difference between the two ADAR1 isoforms,
p150 and p110, is also an important factor to consider when
determining ADAR1’s role in human disease. Earlier studies
characterized p110 as constitutively expressed, while p150 is
interferon-inducible and the main isoform responsible for innate
immune response modulation and AGS (93, 95, 132, 133). In the
context of cancers and metabolic diseases, not all ADAR1-related
studies have clearly differentiated the involvement between p150
and p110, creating potential issues to pinpoint the underlying
mechanisms. As our understanding of functional distinctions
between p150 and p110 improves overtime, there will be
a need to revisit their individual roles in different diseases
(97, 134–136).
As mentioned previously, APOBECs are better known for
their abilities to edit DNAs in viral and tumor genomes. Recent
identifications of APOBEC3A-mediated G-to-A RNA editing
and APOBEC3G as a novel RNA editase signaled that (i) other
APOBECs could also engage in RNA editing activities; and (ii)
APOBEC-mediated RNA editing is not limited to the conversion
from C to U (74, 137). In fact, APOBEC3A was recently shown
to be a C-to-U RNA editase in immune cells, making it the
first proven RNA editase capable of performing multiple RNA
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FIGURE 7 | APOBEC1-mediated RNA editing in metabolic disorders. The color of the first arrow in each pathway indicates the mechanism (refer to Figure 1) by
which APOBEC1 regulates its direct targets, depicted in pink shapes. Additional activators of specific pathway steps are depicted in red rounded rectangles. Gray
arrows point to ApoB-associated secondary functions. ER, endoplasmic reticulum; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein. The figure was
created with BioRender.
editing conversions (138). Further, albeit indirect, evidence to
support these hypotheses is the recent realization that ADARs,
well-known for their RNA editing functions, are also capable
of performing DNA editing (139, 140). These developments
spotlight not only the significance of carefully establishing the
“Enzyme-Target-Function” connections, but also the untapped
potential in uncovering the vast network of RNA editing in the
context of human disease.
RNA Editing-Independent Functions
The effects between RNA and DNA editing can be distinguished
through careful planning and execution of sequencing strategies.
RNA editases, however, possess functions that are independent of
their RNA-editing abilities. RNA editing-independent functions
of ADARs were first noted in their effects on miRNA expression.
Both ADAR1 and ADAR2 are capable of influencing miRNA
expression by either directly interacting withmiRNAs or affecting
miRNA biogenesis through regulation of important factors, such
as Dicer, Drosha or DGCR8 (DiGeorge Syndrome Critical Region
8) (141–143). RNA editing-independent functions of RNA
editases play prominent roles in the processes of proliferation,
metastasis, and immune evasion during tumorigenesis (49, 144–
146).
The RNA editing-independent functions of ADARs have
been demonstrated by utilizing their catalytically inactive
forms. This approach has helped identify these non-catalytic
functions beyond the confines of miRNA biogenesis. The
MAPK-phosphorylated ADAR1 p110 isoform can be shuttled by
Exportin-5 to the cytoplasm, where it protects the expression
of anti-apoptotic genes by competitively inhibiting binding of
Staufen1 to their 3′UTRs (134). In metastatic melanoma, RNA
editing-incompetent ADAR1 is able to negatively regulate the
expression of the metastatic enhancer integrin beta-3 (ITGB3) by
(i) inhibiting the transcriptional activator of ITGB3, PAX6, and
(ii) promoting FOXD1-mediated induction of miR22 to block
ITGB3 translation (147). As mentioned previously, catalytically
inactive ADAR2 mimics WT ADAR2 in an overexpression
mouse model causing hyperphagia and obesity, dissociating this
phenotype from ADAR2’s RNA-editing capability (106).
Little information is available regarding RNA editing-
independent functions of C-to-U editases, such as APOBEC1.
However, APOBEC-mediated functions that don’t require its
deaminase domains have been reported in humans and other
species (148, 149). Asmore functional studies of RNA editases are
reported, clear differentiations between RNA editing-dependent
and –independent mechanisms will be necessary to adequately
assess their contributions to the development of cancers and
metabolic diseases.
Regulations of RNA Editing
RNA-editing events are subjected to highly precise regulatory
mechanisms. Mechanisms that regulate general localization and
expression of RNA editases have been well-studied (9, 10).
Functional regulation of RNA editing in the context of cancer
and metabolic disease, however, remains a gap in our knowledge.
Depending on the tissue of origin and disease stage, different
cancers have been associated with overall induction or reduction
of RNA-editing levels (12, 13, 18). Even in diseases with either
a clear overall editing profile (hyper- vs. hypo-editing) or an
apparent alteration of RNA editase expression, many targets
are edited in the opposite manner (12). Moreover, alterations
of a single editase do not always yield the same result, as
demonstrated by the aforementioned pro- and anti-tumorigenic
functions displayed by both ADAR1 and ADAR2 in different
cancers.
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More dramatic examples can be found in situations where the
same editing event leads to completely different functional or
phenotypic outcomes. Such examples include ADAR1-mediated
editing of GLI1 and ADAR2-mediated editing of COPA in
tumorigenesis (15, 26, 27, 53). APOBEC1-produced apoB48 and
its full-length counterpart apoB100 contribute to developments
of atherosclerosis and obesity to different extents based on the
surrounding regulatory environment (119, 125). Even replicating
a complex editing profile on one target, such as editing of 5-
HT2cR, could result in opposite phenotypes (obesed vs. lean) in
two different animal models (109, 150).
Several regulatory mechanisms of RNA editing have been
recently identified. In aggressive forms of BC, such as triple-
negative BC and metaplastic BC, the presence of ADAR1
is important for their tumorigenic capacity. Recent studies
found that in these cancers, the expression and activity of
ADAR1 can be regulated by tumor-promoting proteins CPSF6
(cleavage and polyadenylation factor-6) and mutant RPL39
(ribosomal protein L39, A14V). CPSF6 interacts with ADAR1
to stabilize its localization and enhance its RNA editing activity
(151). Moreover, CPSF6-mediated activation of ADAR1 can
be inhibited by prolactin, a mammary differentiation factor.
The oncogenic mutant of RPL39 (A14V) induces expression of
ADAR1 to promote tumor growth and chemoresistance through
the functions of iNOS (inducible nitric oxide synthase) and
activated STAT3 (152).
In the brain, where functions of ADAR2 have been extensively
studied, a splicing factor SRSF9 (serine and arginine rich splicing
factor 9) was found to repress ADAR2-mediated RNA editing.
SRSF9 interacts with ADAR2 and its editing targets in the nucleus
to disrupt the formation of ADAR2 dimer, which is necessary
for the editing of genes involved in controlling cell survival
(153, 154). These findings also signaled the importance of the
splicing machinery in the regulation of RNA editing (155). In
CRC, PKCζ (protein kinase C zeta) phosphorylates ADAR2
to activate its RNA editing activity. Phosphorylated ADAR2
inhibits liver metastasis of CRC by promoting the accumulation
of miR-200, potentially through editing of COPA and other
targets (54).
Considering the complex relationship between ADAR1-
and ADAR2-mediated RNA editing, it is not surprising that
mechanisms exist to regulate their RNA-editing functions
simultaneously. One recent example of this is the RNA helicase,
DHX9 (DEAH box helicase 9). By using an overexpression
system in an esophagus carcinoma cell line (EC109), DHX9
was found to preferentially promote and repress ADAR1- and
ADAR2-mediated RNA editing, respectively (156). The end
result is a strong correlation between DHX9 expression and
tumorigenesis. High-throughput screening has been employed
to identify endogenous regulators of ADAR-mediated RNA
editing (157, 158). Attempts to identify additional enhancers
and inhibitors, both intrinsic and extrinsic, of the RNA editing
machinery are ongoing.
APOBEC1-mediated C-to-U RNA editing is carried out
in a multiprotein “editosome” (159). Many components that
are important for the function of this editosome have been
identified, including ACF (APOBEC1 complementation factor),
HNRNPAB (heterogeneous nuclear ribonucleoprotein A/B; or
ABBP-1), DNAJB11 (DnaJ heat shock protein family member
B11; or ABBP-2), KSRP (KH-type splicing regulatory protein),
CELF2 (CUGBP Elav-like family member 2; or CUGBP2),
SYNCRIP (synaptotagmin binding cytoplasmic RNA interacting
protein; or GRYRBP), and RBM47 (RNA binding motif protein
47) (160–166). A rare negative regulator of this editosome,
BAG4 (Bcl2-associated Athanogene-4), was found to suppress
APOBEC1-mediated RNA editing by shuttling APOBEC1 to the
cytoplasm (167). Aside from ACF and RBM47, the physiological
significance of these regulators remains to be confirmed beyond
in vitro experiments (166, 168).
Although more investigations are needed to confirm the
roles of these APOBEC1 partners in APOBEC1-regulated
cancer development, an interesting study using a mouse model
of testicular germ cell tumors (TGCTs) hinted strongly at
such connections. Using 129/Sv inbred mice that develop
spontaneous TGCTs, Apobec1 deficiency was found to affect
TGCT susceptibility either alone or in combination with
mutations of Dnd1 (Deadend1), another TGCT risk factor
that shares strong sequence homology with Apobec1-editosome
member Acf (169). Pending validation of the involvement
of Apobec1-mediated RNA editing in this model, this result
suggests that APOBEC1-mediated impact on tumorigenesis is
subjected to complex regulatory mechanisms, possibly involving
one or more members of the editosome. More interestingly,
the effect of Apobec1 deficiency on TGCT susceptibility was
influenced by the context of germ-lineage (maternal vs. paternal)
and it manifests in a transgenerational manner. It suggests that
APOBEC1 regulates heritable epigenetic changes, presumably
through RNA-editing, to impact the development of human
diseases such as testicular cancer (170).
One major regulator of metabolism, peroxisome proliferator-
activated receptor alpha (PPARα), impacts APOBEC1-mediated
RNA editing in vivo. In mice lacking LDL receptor, PPARα
agonist ciprofibrate (a common cholesterol-lowering drug)
reduces hepatic RNA editing of apoB by decreasing the
expression of Acf (171). The result is increased accumulation
of apoB100-associated VLDL and atherosclerosis. It also
demonstrated that regulatory mechanisms of RNA editing
could impact human diseases by affecting their response to
treatments.
Since RNA editing plays a prominent role in cancer
development, tumorigenesis-associated pathways and factors
could prove to be important regulators of the machinery. For
example, tumor suppressor protein TP53 is involved in nearly
all aspects of tumorigenesis, but few connections have been
made between TP53 and RNA editing (172). So far, TP53 has
only been deleted to create viable cell models to study ADAR1-
mediated RNA editing in the innate immune response (93). The
fact that TP53 status influences the ADAR1-associated phenotype
indicates a larger role for TP53 in the world of RNA editing.
A recent study identified IFI16 (interferon gamma inducible
protein 16) as a common interacting partner of ADAR1 and p53,
strengthening this possibility (173).
There are stronger hints for roles of another TP53-related
protein, ARF (alternative reading frame; or CDKN2A/p14), in
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RNA editing. ARF is well known for its ability to activate TP53
by inhibiting MDM2 (mouse double minute 2), but many TP53-
independnet functions of ARF have also been identified (174).
One of such functions was recently demonstrated in triple-
negative BCs, where ARF collaborates with TP53 to suppress a
tumor-promoting inflammatory pathway involving interferon-β
and STAT1, which are also important factors in ADAR-mediated
RNA editing (90, 93, 132, 175). Combined with the fact that both
ARF and ADAR use the nucleolus as a critical hub, it seems
to place ARF in close proximity to the center of RNA editing
universe (176–178).
As our understanding of RNA editing in cancers and
metabolic disorders improves, it is likely that many other
connections will be discovered between RNA editing and
established factors associated with these human diseases.
Opportunities for Therapeutic Applications
With greater understanding of the relationship between RNA
editing and human disease comes the opportunity for innovative
therapeutic approaches. RNA-based therapies, which include
targeting both RNA itself and its modifications, are becoming
viable options to slow down or even reverse the course of
human disease (179–181). This warrants further investigation of
the mechanisms of RNA-editing and including it as an integral
part of RNA-based therapies. Indeed, not only the overall role
of RNA editing is being studied in various diseases, but also
creative molecular technologies are being developed to identify
and verify specific RNA editing events using cell lines or clinical
samples (12, 17, 182). High-throughput sequencing and “omics”
profiling enable researchers to create comprehensive “maps” of
RNA editing in the human transcriptome (158, 183, 184). A
recent study integrated genomic, transcriptomic, and proteomic
data to pinpoint RNA editing events that are directly responsible
for proteomic diversity leading to disease-relevant alterations in
cancer samples (15).
Modulation of RNA Editing
In principle, modulating the expression or activity of RNA
editases is a reasonable strategy for treating diseases driven
by dysregulated RNA editing. In cancer cells with elevated
ADAR-mediated RNA editing, such as breast and lung cancers,
downregulation of ADAR expression reduces their tumorigenic
capacity (17, 39, 185). To counteract apoB48-mediated
chylomicron formation and lipid absorption, expression of
APOBEC1 was reduced to create transgenic rabbits that are
resistant to diet-induced obesity (122). Beyond altering the
expression of RNA editases, molecular tools are also being
developed to perform selective inhibition of RNA editing. For
example, target-specific inhibition of RNA editing has been
demonstrated by using either morpholino-based or 2′-O-
methyl/locked nucleic acid mixmer antisense oligonucleotides
(186, 187).
In situations where the RNA editing level is inversely
correlated with disease progression, promoting RNA editing
could have beneficial effects. In cancer cells where ADAR2
is downregulated, overexpression of ADAR2 displays tumor-
suppressive activity (16, 53). Overexpression of APOBEC1
combined with an endothelial functional modulator, SR-BI
(scavenger receptor, class B, type I), was tested in a cell culture
model to show anti-atherogenic potential by altering lipoprotein
composition and increasing nitric oxide levels (188). To augment
the effect of RNA editing, artificial and manipulatable tools have
been engineered to control the RNA editing machinery. SNAP-
tag technology was used to assemble, through covalent bonding, a
RNA-editing complex containing the catalytic domain of ADAR1
and a guide RNA. By integrating a light-sensitive protection
molecule between the editase and the guide RNA, the target–
specific RNA editing machinery can be switched on and off via
light (189).
Application of RNA Editing
The concept of creating a RNA-guided editase has been adopted
to attempt target-specific RNA editing. Proof-of-principle studies
have been conducted to demonstrate the potential to target
disease-relevant genes and restore proper protein function
through RNA editing (190, 191). This strategy has also been
applied through the CRISPR (Clustered Regularly Interspaced
Short Palindromic Repeats)-Cas genomic editing system. By
fusing the deaminase domain of ADAR2 with a catalytically
inactive Cas13, this complex can be led by a guide RNA to
perform specific and robust RNA editing (192, 193). Continuous
efforts to increase the efficiency, reduce off-target editing, and
promote simultaneous editing of multiple targets, will push these
technologies closer to therapeutic application (194, 195).
Unintended Consequences and Unique Opportunities
As intriguing as the idea to reverse disease conditions by
modulating RNA editing levels, it is not without potential
drawbacks. Since different human diseases are associated
with either elevated or reduced levels of RNA editing,
altering it one way or the other poses the risk of undesired
consequences. For example, it is theoretically possible to
modulate the overall levels of inosine-containing RNA by
regulating ribonuclease V (196, 197). But dysregulation of
ribonuclease V has been linked to cancers and psychiatric
disorders, indicating the potential hazards (198, 199).
This concern can be extended to approaches targeting
an individual RNA editase, as mutations of ADAR1 and
ADAR2 have been linked to devastating genetic diseases
(95, 200).
In addition to impacting disease progression, RNA editing
could also affect drug response. In MM, ADAR1-mediated
RNA editing promotes immunomodulatory drug resistance (26).
APOBEC1-mediated RNA editing of apoB influences the liver’s
response to lipid-lowering drugs like fibrates (171). Moreover,
ADAR1 can directly alter the cellular response to a drug
by regulating the RNA editing and expression of xenobiotic-
metabolizing-related factors, such as AhR (aryl hydrocarbon
receptor) and CYP1A1 (Cytochrome P450, family 1, member A1)
(201). These studies highlight potential side-effects of both stand-
alone and combinatorial therapies involving modulation of RNA
editing.
Man-made, RNA-guided, and target-specific RNA editing has
the potential to become the next revolution in (epi)genetic
Frontiers in Endocrinology | www.frontiersin.org 14 December 2018 | Volume 9 | Article 762
Kung et al. RNA Editing in Cancer and Metabolic Disease
therapy. It offers a unique opportunity to modulate protein
functions without altering the sequence and integrity of
the genome. Indeed, its unique characteristics haven’t gone
unnoticed and RNA editing has been incorporated into cutting-
edge technologies, such as CRISPR-Cas genome editing (192).
Recent studies pointing out the potentially crippling effects
of genome editing, however, should serve as a cautionary
tale when considering using RNA editing in a similar
fashion (202–205). Further studies are needed to ensure the
efficacy and safety of this approach before considering clinical
applications.
Having mentioned the potential problems, it should be
acknowledged that there are tremendous opportunities for RNA-
editing-based therapies to treat human diseases. By engaging
biological events at the RNA level, RNA-editing could be
associated with many-to-one or one-to-many relationships
between RNA editases/events and downstream effects. Examples
of “many-to-one” include the “see-saw” effect of PODXL
editing by ADAR1 and ADAR2 in GC, and the ability
of both ADAR1 and ADAR2 to regulate biogenesis of
miRNA let-7 (31, 49, 58). It points out common downstream
effectors of multiple editases, offering therapeutic targets
that are more specifically linked to diseases. There are also
“one-to-many” cases, such as the association of ADAR2-
mediated editing of miR376 with both glioblastoma and
metabolic disorders (51, 105). Intervention strategies targeting
“ADAR2-miR376” as a unit thus could have broader range of
applications.
The relationship between cancer development and metabolic
disorders has been strengthened in recent years, and it appears
to be a two-way street. It is well-established that cancers
often overcome unwanted stresses by hijacking metabolic
pathways, and metabolic disorders like obesity and diabetes are
strong predisposing factors to cancers (206, 207). Reversely,
cancers can create systematic metabolic imbalances in patients
resulting in metabolic diseases such as diabetes or CVD
(208, 209). Understanding the cross-talk between cancer and
metabolic diseases is one of the most critical challenges for
human health, and RNA editing is an important piece of the
puzzle.
CONCLUSION
As this review shows, there has been an explosion of information
regarding RNA editing in the last 3–5 years. This is indeed
an exciting time to study this unique epigenetic phenomenon,
with plenty of opportunities and challenges ahead. Some burning
questions, as highlighted throughout this review, will need to be
answered in the near future. How is new information used to
reshape the central dogma of cell biology of “DNA to RNA to
protein?” Are there more RNA editases waiting to be discovered?
How do we reliably identify RNA editases, and corresponding
editing events, in specific human diseases? Can part of the
RNA editing machinery be targeted as a monotherapy, or is
combining these interventions with other parallel treatments,
such as immunotherapy, a better course of action?
Outside the purview of this article, RNA editing also plays
significant roles in other physiological conditions, such as
infectious, inflammatory/autoimmune, and neurodegenerative
diseases (210–213). It will be interesting, in some cases necessary,
to investigate the inter- and intra-relationships between the
roles of RNA editing in these diseases with those in cancers
and metabolic disorders. The ultimate goal is to leverage this
information into actionable therapeutic innovations. More than
30 years after its initial discovery, the significance of RNA editing
in human disease is being recognized more than ever.
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